<DOC>
	<DOC>NCT00638716</DOC>
	<brief_summary>This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Major BMI: 27 to 45 kg/m2 Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator Stable lifestyle, i.e. diet &amp; physical activity, as determined by the Investigator Stable metformin daily dose ≥1000 mg for at least 3 months Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Type 2 Diabetes Mellitus, incretins, GLP-1, HbA1c, metformin</keyword>
</DOC>